http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2232813-C1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 |
| filingDate | 2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2004-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6e7ca969222f068bb8eef91a30a4d76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_546c0c831f8f889b48910aaf45c9507c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2086d61f1c21ef5559f01894688079b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fd133730ac501165fa8abff58211aa8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac7aa0b2d17f072c44bb67140409cbdf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8349fbb1acfece75139791a4aac75e73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b86eac8bbfc12914f037bda7900fe23d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e70b8555bdcf7ee34f94f06194b1fe81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d12f5e813cd99a7bdc7ef43ece63a6ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0721bc3da3e8e54affa39d23f419098 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6a21d41086e8f2c24c1a7dbd46d4fedf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86daa510b2d7ea2e60087bf7d06b8e61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d31eefac0038ddad1c37fa5f8469416c |
| publicationDate | 2004-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2232813-C1 |
| titleOfInvention | Method for industrial preparing human recombinant insulin |
| abstract | FIELD: biotechnology, hormones. n SUBSTANCE: invention can be used for preparing human recombinant insulin used for preparing medicinal preparations in treatment of diabetes mellitus. Culturing the strain-producer E. coli JM109/pPINS07 is carried out in industrial fermenter of volume 200-1500 l. The concentration of dissolved oxygen is maintained at the level 40 ± 15%. Cells are disrupted by disintegration and inclusion bodies are dissolved in 8 M urea-containing buffer followed by addition of dithiothreitol. Renaturation of the insulin fusion protein is carried out for a single stage by incubation in 5-10-fold excess of buffer before the purification stage by acid precipitation. Fusion protein is subjected for chromatography on KM-Sepharose. Enzymatic cleavage is carried out successively in the ratio trypsin : fusion protein and carboxypeptidase B : fusion protein = 1 : (500-1000). Between stages of fusion protein cleavage with trypsin and carboxypeptidase B chromatography on SP-Sepharose is carried out. Insulin is purified by method of reversed-phase high-performance liquid chromatography and the following gel-filtration and isolation of the end product in the presence of zinc salts. Invention provides simplifying the preparing highly purified human recombinant insulin and to enhance the yield in the industrial scale. n EFFECT: improved preparing method. n 5 cl, 4 tbl, 1 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009041858-A1 |
| priorityDate | 2003-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.